中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 772-775.
DOI: 10.19803/j.1672-8629.2021.08.16

• 安全与合理用药 • 上一篇    下一篇

HLA-B*5801基因检测在别嘌醇严重过敏反应评价中的应用分析

方玲1, 董敏2, 汪燕燕1,*   

  1. 1安徽医科大学第一附属医院药剂科,安徽 合肥 230022;
    2中国医学科学院药物研究所,北京 100050
  • 收稿日期:2019-12-26 出版日期:2021-08-15 发布日期:2021-08-17
  • 通讯作者: *汪燕燕,女,硕士,副主任药师,临床药学。 E-mail: wyybj2007@163.com
  • 作者简介:方玲,女,博士,主管药师,临床药学。
  • 基金资助:
    国家自然科学基金资助项目（81600498）; 中华医学会临床药学分会基金资助项目（320.6750.19090-17）

Applicability of HLA-B*5801 Allele Detection in Allopurinol Irritated Severe Allergic Reactions

FANG Ling1, DONG Ming2, WANG Yanyan1,*   

  1. 1Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Hefei Anhui 230022, China;
    2Institue of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China
  • Received:2019-12-26 Online:2021-08-15 Published:2021-08-17

PDF (PC)

102

摘要： 目的 汉族人群中HLA-B*5801基因与别嘌醇严重过敏反应存在强相关性,分析我院HLA-B*5801基因检测结果及其在别嘌醇临床应用情况,为减少别嘌醇不良反应提供参考。方法 回顾性调查我院2017年1月1日~2017年12月31日进行HLA-B*5801基因检测的住院患者临床资料,分析和评价基因检测结果应用情况。结果 共纳入检测HLA-B*5801基因患者55例,肾脏内科39例,皮肤性病科13例,内分泌科3例。检测结果阳性者17例（30.91%）,阴性者38例（69.09%）。用药后出现皮肤不良反应的患者共13例,基因检测结果阳性11例,阴性2例。所有患者中有30例（54.55%）按照指南推荐在用药前检测了HLA-B*5801基因。结论 我院患者服药前按照指南检测HLA-B*5801基因的比例偏低,药学部门应重视对临床别嘌醇用药监管。应提倡根据基因检测结果用药,减少药品不良反应发生风险。

关键词: HLA-B*5801, 别嘌醇, 药品不良反应

Abstract: Objective To analyze the detection results of HLA-B*5801 and clinical applicability of allopurinol in our hospital in order to provide information for preventing allopurinol-caused adverse reactions. Methods The clinical information about patients who had their HLA-B*5801 detected between January 1, and December 31, 2017 in our hospital was retrospectively analyzed. The applicability of gene detection results was assessed. Results A total of 55 patients who had received gene detection were collected, including 39 from the Department of Nephrology, 13 from the Department of Dermatology, and 3 from the Department of Endocrinology. There were 17 (30.91%) HLA-B*5801 allele positive cases,38 (69.09%) negative cases. Thirteen patients suffered from cutaneous adverse reactions after allopurinol treatment, eleven of whom were HLA-B*5801 allele positive and 2 were negative. Among these patients, 30 (54.55%) had had their HLA-B*5801 gene tested before allopurinol therapy according to the guidelines. Conclusion The proportion of patients who have their HLA-B*5801 gene detected before allopurinol therapy in our hospital is relatively low. The pharmaceutical department should strengthen the supervision of clinical use of allopurinol. It is recommended that this drug be used according to the results of gene test to minimize the risk of adverse reactions.

Key words: HLA-B*5801, allopurinol, adverse drug reactions

中图分类号: